Target intelligence / Profile preview

Envelope glycoprotein (Env), Group-specific antigen (Gag), Polymerase (Pol), Negative regulatory factor (Nef) of human immunodeficiency virus type 1 (HIV-1 Env, Gag, Pol, and Nef)

Target
HIV-1 Env, Gag, Pol, and Nef
Molecular classification
Structural protein (Gag, Env), Enzyme (Pol—includes reverse transcriptase, integrase, protease), Accessory/regulatory protein (Nef), Viral antigen, Polyprotein precursor
01

Overview

Envelope glycoprotein (Env) is a heavily glycosylated HIV-1 protein forming trimeric “spikes” on the virion surface, mediating receptor binding (via gp120) and fusion with host cells (via gp41).\nGroup-specific antigen (Gag) is a polyprotein cleaved into matrix (p17), capsid (p24), and nucleocapsid (p7) proteins, essential for virion assembly, RNA packaging, and particle release.\nPolymerase (Pol) is translated as part of Gag-Pol polyprotein; it encodes protease, reverse transcriptase, and integrase enzymes for proteolytic processing, genome replication, and integration.\nNegative regulatory factor (Nef) is an accessory protein involved in immune evasion, modulation of cell surface proteins, enhancement of viral infectivity, and downregulation of CD4 and MHC I on host cells.\nAll four are major antigens and targets in vaccine studies, with Env showing the greatest variability across viral strains and Gag/Pol more conserved. They are associated with disease progression and serve as primary molecular targets for antiretroviral drugs (primarily Pol) and experimental immunotherapies (Gag, Env, Nef).\nNote: For structured annotation, each protein (Env, Gag, Pol, Nef) should be treated as a separate target for precision. This bundled name is sometimes used in vaccine/antigen research but is not itself a canonical target name in pharmacology or molecular biology.

Other names
HIV envelope protein (Env)HIV matrix/capsid/nucleocapsid proteins (Gag)HIV polymerase enzymes (Pol)HIV negative factor protein (Nef)gp120, gp41 (components of Env)p17, p24, p7 (Gag cleavage products)Gag-Pol polyproteinHIV accessory protein Nef
02

Mechanism of action

Reverse transcriptase inhibitors block DNA synthesis by Pol (reverse transcriptase)\nIntegrase inhibitors prevent viral DNA integration into host genome by Pol (integrase)\nProtease inhibitors block proteolytic maturation of viral polyproteins by Pol (protease)\nFusion inhibitors block Env-mediated membrane fusion\nMonoclonal antibodies neutralize Env\nVaccine approaches elicit immune responses targeting Gag, Pol, Env, and Nef antigens

03

Biological functions

Virion assembly (Gag, Env)Virion budding and release (Gag)Genome packaging (Gag)Membrane fusion and entry (Env)Reverse transcription, integration, proteolytic processing (Pol)Immune evasion and pathogenicity (Nef)Modulation of host cell signaling (Nef)
04

Disease associations

Infection (human immunodeficiency virus/AIDS)Immune system dysregulationPathogenicity (Nef)
05

Safety considerations

Off-target immune responses, especially with vaccine strategies that include multiple antigensAntigenic variability, especially in Env, presents challenge for broad efficacyInduction of immune escape variantsRisk of autoimmunity or excessive inflammatory responses
06

Interacting drugs

*Pol*: Reverse transcriptase inhibitors (e.g., zidovudine, efavirenz), integrase inhibitors, protease inhibitors

2 more in the full profile.

07

Biomarkers

HIV p24 antigen (Gag product)HIV RNA and DNA viral load (indirect, monitors presence/level)Anti-Env, anti-Gag antibody titers for monitoring vaccine efficacyCD8+ T-cell responses against these antigens for immunogenicity assessment

Beyond the preview

Go deeper on Envelope glycoprotein (Env), Group-specific antigen (Gag), Polymerase (Pol), Negative regulatory factor (Nef) of human immunodeficiency virus type 1 (HIV-1 Env, Gag, Pol, and Nef).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Envelope glycoprotein (Env), Group-specific antigen (Gag), Polymerase (Pol), Negative regulatory factor (Nef) of human immunodeficiency virus type 1 (HIV-1 Env, Gag, Pol, and Nef).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call